Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | LTA4H | P09960 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | BAX | Q07812 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19392583 | 1.00 | RAB9A (0.65) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL13403329 | 0.94 | MAPT (0.59) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| Diphenylether SCHEMBL16592512 | 0.93 | LTA4H (0.60) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL427816 | 0.90 | RAB9A (0.77) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL18118972 | 0.90 | RAB9A (0.77) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL127279 | 0.90 | RAB9A (0.77) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL19392589 | 0.88 | RAB9A (0.53) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL685353 | 0.88 | RAB9A (0.53) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL29377311 | 0.87 | RAB9A (0.74) | RAB9AMAPTNPC1HPGDALDH1A1 | |
| SCHEMBL686069 | 0.87 | RAB9A (0.52) | RAB9AMAPTNPC1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-12029111-B2 | Oxygen heterocyclic compound, application thereof and electronic device using the same | WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12029111-B2 | Oxygen heterocyclic compound, application thereof and electronic device using the same | WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-19 | — | — | US | disclosed |
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-19 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| CN-1088579-C | Antiplaque oral composition | COLGATE PALMOLIVE CO (US) | 2002-08-07 | — | — | CN | disclosed |
| US-6395939-B1 | CATALYTIC ETHERIFICATION AND CONDENSATION WITH COPPER CATALYSTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-05-28 | — | — | US | disclosed |
| WO-1999018057-A1 | PREPARATION OF DIARYL ETHER BY CONDENSATION REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-04-15 | — | — | WO | disclosed |
| CN-1200025-A | Antiplaque oral composition | COLGATE PALMOLIVE CO (US) | 1998-11-25 | — | — | CN | disclosed |
| US-5814646-A | TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| US-5432273-A | Cyclizing a 5-(protected)oxy-5-(heterocyclic base)-3(S)-fluoro-1,2-(S)-pentanediol | EMORY UNIVERSITY (US) | 1995-07-11 | — | — | US | disclosed |
| US-5414078-A | Preparation of 3'-substituted-2',3'-dideoxynucleosides and 2'-deoxynucleosides from acyclic, achiral precursors | EMORY UNIVERSITY (US) | 1995-05-09 | — | — | US | disclosed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | disclosed |
| US-4066707-A | METHOD FOR MANUFACTURE OF DIPHENOLS AND MONOALKYL ETHERS OF DIPHENOLS | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JA) | 1978-01-03 | — | — | US | disclosed |
| US-3939113-A | ANTHRAQUINONE DYES | CIBA-GEIGY CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029111-B2 | Oxygen heterocyclic compound, application thereof and electronic device using the same | AOC2, AOX1, TYR | RAB9A 2784/4885MAPT 2401/4885NPC1 2611/4885 |
| US-20230330061-A1 | ANTIMICROBIAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | FASN, NAAA, FPR3 | RAB9A 2453/4885MAPT 1959/4885NPC1 643/4885 |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | RAB9A 905/4885MAPT 3815/4885NPC1 738/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | RAB9A 2641/4885MAPT 2731/4885NPC1 2024/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | RAB9A 2580/4885MAPT 3123/4885NPC1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.